Elevance Health Inc (ELV)

Investment Committee Summary

Investment Thesis

At $413 (10 October 2026) Elevance trades near 15x forward earnings, a discount to the managed-care peer median. Spot implies the market expects membership growth to persist but treats the margin as structurally capped, with Medicaid and reform risk overhanging the multiple. The engine's read sits close to the tape: the probability-weighted expected value of $371 and the twelve-month target of $375 are modestly below the current quote, and triangulation at $337 leaves the shares trading rich to that anchor (-18%), so the rating is HOLD. The disagreement is narrow. The base path assumes high-single-digit premium growth on an operating margin near 3.5% (reported GAAP, TTM to Jun 2026), a genuinely thin margin on a very large premium base, which is the central fact of this business. Upside in the growth and re-rating paths depends on care-services mix and Medicare Advantage margin recovery lifting earnings and the multiple together, but those paths carry only a minority of the weight, and the capex-bridge discounted-cash-flow anchor sits below the current price, which restrains conviction. A balance sheet carrying net debt of ~$22.2B adds financing sensitivity to an already thin margin. The single most damaging risk is a sustained medical-cost-trend spike: with the benefit-expense ratio already elevated, two consecutive prints above plan push earnings toward the cost-trend path and the target below current levels.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($413) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear mechanism is the base path itself failing, not a tail event. Elevance earns a very thin operating margin on an enormous premium base, so the entire thesis rests on medical-cost trend staying inside priced rate. It has not reliably done so: operating cash flow has converted at well below net income, a sign of reserve pressure rather than of timing. Medicaid redeterminations continue to strip lower-cost members from the risk pool while rate updates lag actual utilisation. If the benefit-expense ratio holds above plan for two consecutive prints, the margin compresses by a fraction of a point, which on this base is a large proportion of earnings, and the multiple de-rates in tandem because the market reprices earnings quality rather than merely the level. That combination alone moves fair value toward the cost-trend path, a large drop from the current quote, without needing any structural reform, and net debt of ~$22.2B limits the buyback that would otherwise cushion it.

Key Debate

Gross Margin explains 67% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 15.2× consensus forward EPS, vs the house DCF terminal 12.0×, and a peer median 19.7×. The house DCF sits 24% below spot, so the market is pricing in more than the house case — roughly 2.1pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Medicare/Medicaid Reform / MLR Squeeze' downside ($159) to a 'Bull — Margin Recovery / Re-Rate' bull case ($668); the probability-weighted blend (PWEV $371) is -10% versus spot.

SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (1.5% of shares, on SBC ≈ 0% of revenue), trimming the gross PWEV of $377 to $371 (-1.5%). SBC is charged once, as dilution — never also deducted from FCF.

Scenario rationale — the driver path behind every target:

• Structural — Medicare/Medicaid Reform / MLR Squeeze (20%, $159). Structural impairment — Medicare/Medicaid reform / MLR squeeze: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Cost-Trend Spike / Rate Inadequacy (17%, $272). Cyclical downturn — membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy weakens for 1–2 years before normalising.
• Base — Membership + Premium Growth (35%, $399). Mid-cycle — normalised membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy; disciplined capital allocation; steady returns.
• Growth — MA / Care-Services (Optum-style) (20%, $530). Upside — MA + care-services growth lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Margin Recovery / Re-Rate (8%, $668). Upside tail — sustained tight conditions or a structural re-rate on MA + care-services growth.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $335 + scenario PWEV $371, ≈ spot); the weighted blend $337 (-18%) sits below it because the exit-multiple DCF ($314) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $335 and 37% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (67% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — explicit-period cash flows with an exit-multiple terminal

A 5-year cash-flow path discounted at a WACC of 8.5%, plus a terminal value of final-year FCF × 12.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $314. The terminal value is 70% of enterprise value, so this anchor moves with the multiple assumption. The heaviest anchor in this blend (47%); because its terminal is a market multiple, it is not independent of the multiple-driven anchors.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $509; the peer-median forward P/E is 19.7x, but the engine carries no P/E-implied price for this name (fewer than three same-sub-industry peers carry a forward multiple). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 52% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)

Tornado — DCF/share swing by driver (widest first)

Company lever — value at the base multiple vs Managed Care / Health Services multiple (base 14.0x)

Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.

Peer Quality & Weighting

Quality-weighted forward P/E: 18.7× (simple median 19.7×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $275–$436, centre $346 (-16% vs spot); spot sits at the 85th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio is (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Medicare/Medicaid Reform / MLR Squeeze' target ÷ price). 'Structural — Medicare/Medicaid Reform / MLR Squeeze' ($159, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. With a leg missing the ratio is withheld rather than computed from a magnitude. Bull case (Bull — Margin Recovery / Re-Rate): $668.

Company Overview & Business Model

Elevance Health Inc — HEALTHCARE · HEALTHCARE PLANS. Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.

Company description as supplied by Alpha Vantage; not checked against the company's filings.

How it makes money.

† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.

Reported operating margin (GAAP): 4.1% for the fiscal year ended 2025-12-31; 3.5% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Edge. Narrow moat — The moat is Blue Cross Blue Shield licensed scale, regulated membership relationships and a growing Carelon services arm, but managed care is a thin-margin, politically exposed, MLR-capped business; that supports only a modest terminal multiple. Falsifiable: the discount to UNH (~22x) reflects less vertical integration — if Carelon/CarelonRx fail to lift consolidated margin above the low-3s and Medicaid redeterminations keep pressuring MLR, the moat stays narrow and the ~14x multiple is fair rather than cheap.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

For comparison, the company's reported GAAP operating margin was 4.1% for the fiscal year ended 2025-12-31; 3.5% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 0% of revenue; cash conversion (OCF/NI) 76% — earnings not cash-backed.

Competitive Moat

Moat sources:

• Blue Cross Blue Shield trademark licenses in 14 states (exclusive local franchises)
• Scale membership base and provider-network contracting leverage
• Carelon / CarelonRx vertically-integrated services (Optum-style pivot)
• Regulatory-embedded position in Medicaid/Medicare Advantage

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.69 vs analyst floor +0.00 → delta +0.69 (n=41 mgmt / 15 Q&A; 97th pctile across the S&P book, z +1.8).

Flag: ELEVATED — management unusually upbeat vs the analyst floor relative to peers (disconfirmation watch).

News (last 365d, 1409 articles): avg ticker sentiment +0.12 (bullish 20% / bearish 7%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-15 (~6d) — 2027 Medicare Advantage Star Ratings release (authored)
• 2026-10-20 (~11d) — Quarterly earnings — est. EPS $4.70 (AV EARNINGS_CALENDAR)
• 2026-11-05 (~27d) — 2027 rate/bid and Medicaid redetermination-completion update (authored)
• 2027-02-10 (~124d) — Carelon services margin and external-growth disclosure (authored)

Forecast Track Record

• EPS surprise: beat 62% of the last 8 quarters; average surprise +7.1%.

Catalyst Timeline

7 catalysts in the next 90 days (of 15 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 1 bearish / 1 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Benefit expense ratio (MLR) >= 89.5% (2 consecutive prints). MLR above the high-88s sustained signals medical-cost trend is outrunning priced rate, pushing the margin toward the Cost-Trend / Rate-Inadequacy path rather than Base.
• Full-year adjusted EPS guidance < $30.00 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• Medicaid membership < prior-year level (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Medicare Advantage Star ratings (share of members in 4+ star plans) < prior-year share (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• Operating cash flow to net income conversion (TTM) < 0.8x (2 consecutive prints). Deteriorating cash conversion flags reserve strengthening or receivables build from cost-trend pressure, corroborating margin stress ahead of the reported MLR.

Fact / Inference / Speculation

• FACT: Spot $413; 52-week range $275–$436; engine rating HOLD; house target $375 (-9%). (source: Alpha Vantage 2026-10-09, 10 October 2026)
• INFERENCE: Triangulated FV $337 (-18% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

58.0/100 (confidence band 47.4–68.5), 52nd percentile of 893 covered names (as of 2026-10-09). Weighted composite under config ros-1.20.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 54.9 → 56.2 → 56.5 → 55.7 → 55.1 → 55.5 → 57.5 → 58.5.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $376.91.

Factor Exposures

Cross-sectional percentiles over 893 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.12, vs QQQ +0.04 (trailing ~1y daily returns).

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -10% vs spot
• Monte Carlo median implies -19% vs spot
• DCF fair value (exit-multiple terminal) implies -24% vs spot — but this is terminal-value sensitive (exit-multiple $314 vs Gordon $437, 39% apart), so it carries less weight
• Bear case (Structural — Medicare/Medicaid Reform / MLR Squeeze) downside is -62% vs spot
• Net: the valuation anchor itself sits 18.3% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 2% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $27B + PV(terminal) $63B = EV $90B; − net debt $22.2B → equity $68B ÷ diluted shares $0.22B = $314/share (exit-multiple terminal).

• Gordon terminal → $437/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
• Incremental ROIC on the forecast capex ≈ 30% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $509 (no P/E-implied price — fewer than three same-sub-industry peers carry a forward multiple).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Model op margin ±3pp (658.0); Revenue CAGR ±3pp (105.0); Terminal × ±15% (87.0); WACC ±1pp (34.0); Capex intensity ±15% (23.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 12×, FY+5 revenue $271B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.